SCHEMBL22292201

SCHEMBL22292201

N#Cc1nc(F)[nH]c1C#N

nearest known ligand 0.46

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.46
MAPK1 P28482 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25468678 0.74
SCHEMBL18320214 0.73 ALDH1A1 (0.47) ALDH1A1MAPK1
SCHEMBL28738454 0.73 ALDH1A1 (0.56) ALDH1A1MAPK1
SCHEMBL13217085 0.71 ALDH1A1 (0.46) ALDH1A1MAPK1
SCHEMBL28847024 0.71 ALDH1A1 (0.46) ALDH1A1MAPK1
SCHEMBL404890 0.71 ALDH1A1 (0.46) ALDH1A1MAPK1
SCHEMBL11662504 0.71 ALDH1A1 (0.46) ALDH1A1MAPK1
SCHEMBL1529256 0.71 ALDH1A1 (0.46) ALDH1A1MAPK1
SCHEMBL30356753 0.71 ALDH1A1 (0.46) ALDH1A1MAPK1
SCHEMBL28997946 0.71 ALDH1A1 (0.46) ALDH1A1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11742518-B2 Electrolyte, and electrochemical device and electronic device using the same NINGDE AMPEREX TECHNOLOGY LIMITED (CN) 2023-08-29 US disclosed
US-20230155173-A1 ELECTROLYTE AND ELECTROCHEMICAL DEVICE USING THE SAME NINGDE AMPEREX TECHNOLOGY LIMITED (CN) 2023-05-18 US disclosed
US-20210408600-A1 ELECTROLYTE, AND ELECTROCHEMICAL DEVICE AND ELECTRONIC DEVICE USING THE SAME NINGDE AMPEREX TECHNOLOGY LIMITED (CN) 2021-12-30 US disclosed
US-10734677-B2 Substituted imidazole and benzimidazole lithium salts ROBERT BOSCH GMBH (DE) 2020-08-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10734677-B2 Substituted imidazole and benzimidazole lithium salts KCNJ11, KCNJ1, KCNJ8 ALDH1A1 1039/4885MAPK1 2950/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.